Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) Net Income towards Common Stockholders (2024 - 2025)

Evommune (EVMN) has disclosed Net Income towards Common Stockholders for 2 consecutive years, with -$28.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders changed N/A to -$28.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$57.3 million, a N/A change, with the full-year FY2025 number at -$77.8 million, down 16.45% from a year prior.
  • Net Income towards Common Stockholders was -$28.3 million for Q4 2025 at Evommune, down from -$12.5 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$12.5 million in Q3 2025 to a low of -$28.3 million in Q4 2025.